Cidara Therapeutics, Inc.

Cidara Therapeutics, Inc. is a risky bet given it's low Altman Z-score. Companies with a low Altman Z-score have a higher chance of going bankrupt within the next 2 years. Cidara Therapeutics, Inc. could be a weak company given it's low Piotroski F-score. The stock has a good momentum. Cidara Therapeutics, Inc. is not a good value stock. Cidara Therapeutics, Inc. is a mediocre stock to choose.

Cidara Therapeutics, Inc. is a biotechnology company, which engages in the discovery, development, a...

News

Cidara Therapeutics trading resumes

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

Cidara Therapeutics Restructures Workforce to Focus on Planned Clinical Development of CD388

Globe Newswire SAN DIEGO, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak platform to develop drug-Fc conjugate (DFC...\n more…

Cidara Therapeutics trading halted, news pending

Cidara to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Globe Newswire SAN DIEGO, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX) (the Company), a biotechnology company using its proprietary Cloudbreak platform to develop drug-Fc conjugate...\n more…

Cidara Therapeutics names Jim Beitel CBO

Cidara Therapeutics Announces Appointment of Jim Beitel as Chief Business Officer

Globe Newswire Appointment adds biotech veteran with over two decades of business development, strategy, and operational experience to Cidara's management teamSAN DIEGO, Aug. 19, 2024 (GLOBE NEWSWIRE) -- Cidara...\n more…